The future of India’s bankrupt Orchid Pharma has been thrown up in the air once again. An appellate body has rejected Dhanuka Laboratories’ offer to acquire Orchid and put the debt-laden company back on the road to recovery. It is the second time a rescue bid for Orchid has collapsed and the news has sent the firm’s share price tumbling.
In late June, The National Company Law Tribunal approved an insolvency recovery plan submitted by privately-held Dhanuka to acquire Orchid, which is headquartered in the southern city of Chennai. The tribunal rejected rival offers from Accord Life Spec and Covalent Laboratories
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?